#	Pagina
attuale pagina	/open-h2020/projects/209444/index.html

Opendata, web and dolomites

EBOMAN

Manufacturing and Development for Rapid Access Ebola Vaccine (EBOMAN) – Sofia ref.: 115850

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

EBOMAN project word cloud

Explore the words cloud of the EBOMAN project. It provides you a very rough idea of what is the project "EBOMAN" about.

stability clinical requiring outcome 4m material improvements generating execute ad26 covers overages topic candidate vaccine manufacturing prepare emergency creation cope urgent filo conjunction boost outbreak ebola released phase subsequently escalation rapid unmet supplies forms accelerating bsl capability quantities additional alternative vaccination characterisation capacity sufficient generation strategy 20m release 300l prime 50l downgrading classification generate performed mva combination investigations transport doses manufacture reflected supply zebov bn reg

Project "EBOMAN" data sheet

The following table provides information about the project.

Coordinator	VIBALOGICS GMBH Organization address address: ZEPPELINSTRASSE 2 city: CUXHAVEN postcode: 27472 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.ebovac.org/eboman/
Total cost	40˙188˙229 €
EC max contribution	1˙023˙325 € (3%)
Programme	1. H2020-EU.3.1.7.13. (Other)
Code Call	H2020-JTI-IMI2-2014-02-single-stage
Funding Scheme	IMI2-RIA
Starting year	2014
Duration (year-month-day)	from 2014-12-01 to 2017-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	VIBALOGICS GMBH VIBALOGICS GMBH Organization address address: ZEPPELINSTRASSE 2 city: CUXHAVEN postcode: 27472 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (CUXHAVEN)	coordinator	1˙023˙325.00
2	BAVARIAN NORDIC AS BAVARIAN NORDIC AS Organization address address: HEJRESKOVVEJ 10 A city: KVISTGARD postcode: 3490 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (KVISTGARD)	participant	0.00
3	JANSSEN VACCINES & PREVENTION BV JANSSEN VACCINES & PREVENTION BV Organization address address: ARCHIMEDESWEG 4 city: LEIDEN postcode: 2333 CN website: www.crucell.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	0.00

Map

Project objective

This topic response (Topic 2: Manufacturing Capability) forms part of an integrated proposal to address the urgent unmet needs of accelerating the development of an Ebola vaccine. To help facilitate this main goal additional activities will be performed; the generation of sufficient vaccine and the capacity increase for generating more vaccine by means of process scale up and improvements.

The main objectives of this proposal are to manufacture sufficient supplies (and overages) for the clinical studies described in topic 1 and to prepare for a rapid access to large quantities of Ad26.ZEBOV (prime) and MVA-BN®-Filo (boost) vaccine in case of further escalation of the Ebola outbreak (The clinical development may change requiring an alternative vaccine combination; vaccination strategy. Any changes will be subsequently reflected in the manufacturing of clinical supplies). In conjunction with topic 3 (Transport and Rapid Access Ebola Vaccine) we should be able to respond quickly to future emergency needs of the vaccine.

The program therefore covers immediate manufacturing of clinical material and creation of additional capacity (by scale up, process improvements) and product understanding (BSL classification downgrading, process and product characterisation) to cope with increased need for the vaccine. The program includes:

Manufacturing, release and supply of Ad26.ZEBOV and MVA-BN®-Filo vaccine candidate for clinical studies (outcome: released clinical material)

Process Development activities required to ensure scale up of Ad26.ZEBOV manufacturing to 50L and fully define the 300L scale MVA BN®-Filo production.

Execute process development activities to ensure scale up of Ad26.ZEBOV and MVA-BN®-Filo to support potential manufacturing of up to 4M doses

Process Development and further scale up to support potential manufacturing of 10-20M doses

Generate material for further stability investigations towards late phase

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOMAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EBOMAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.13.)

EBOVAC1 (2014)

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854

VSV-EBOVAC (2015)

Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

ADAPT-SMART (2015)

Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890